All articles tagged with #idiopathic pulmonary fibrosis
Bristol Myers Squibb (BMS) reported positive Phase 3 results for two experimental drugs, admilparant and RYZ101, as it seeks to offset the impending loss of exclusivity for its blockbuster products Eliquis and Opdivo. While both trials met their primary endpoints, the market reaction was mixed, with BMS stock initially rising before falling, reflecting investor caution regarding safety data and dose efficacy.
Endeavor BioMedicines reported that its Hedgehog inhibitor taladegib met primary endpoints in a phase 2b trial for idiopathic pulmonary fibrosis, showing improved lung function and reduced fibrosis. The results suggest the drug could reverse disease progression, challenging current standard-of-care therapies that only slow decline.
A small clinical trial found that rentosertib, an AI-designed drug for idiopathic pulmonary fibrosis (IPF), may slow biological aging. Patients appeared 3-4 years younger on blood protein tests, though researchers caution this is preliminary and does not prove longevity benefits.
A phase 2a trial of rentosertib, an AI-designed drug for idiopathic pulmonary fibrosis (IPF), suggests it may slow biological aging by 3-4 years. Published in Nature Biotechnology, the study used six proteomic clocks to measure changes in blood proteins, finding that treated patients appeared younger. Researchers caution that the small sample size and disease-specific context limit conclusions, noting that anti-fibrotic effects may confound aging results. A larger phase 3 trial in China is underway to further investigate these dual-purpose outcomes.
A new study in Nature Biotechnology reports that rentosertib, an AI-generated drug developed by Insilico Medicine for idiopathic pulmonary fibrosis, reduced biological age markers in a 12-week phase 2a trial. While promising, experts caution that aging clocks are not yet universally validated, and the drug remains far from regulatory approval.
A phase 2a trial of rentosertib, an AI-designed drug for idiopathic pulmonary fibrosis, shows that the treatment significantly slowed biological aging across six proteomic clocks. While the drug improved lung function, the aging effects were distinct from disease improvement, suggesting potential dual-purpose benefits for aging and fibrosis.
Insilico Medicine reported that rentosertib, an AI-designed drug for idiopathic pulmonary fibrosis, reduced biological age markers in a small clinical trial. Published in Nature Biotechnology, the study analyzed blood samples from 42 patients using six independent proteomic aging clocks. While the drug showed potential to reverse aging indicators by up to three years, experts caution that the results may reflect lung health improvements rather than true anti-aging effects. The findings highlight the promise of AI in drug discovery but require larger trials to confirm efficacy.
Former Yankees star Bernie Williams recalls his father's five-year battle with idiopathic pulmonary fibrosis, a misdiagnosed and incurable ILD, attributing part of the decline to his dad’s 'old-school' reluctance to seek timely care. Williams now advocates for ILD awareness and self-advocacy through Boehringer Ingelheim's Beyond the Scars program, noting that ILD affects about 200,000 Americans and often involves significant diagnostic delays, especially among men.
Researchers have linked a lung microbiome–related gene, TLR5, to idiopathic pulmonary fibrosis (IPF): mice lacking TLR5 show more fibrosis after lung injury, highlighting a genetic pathway that could be targeted by drugs to slow IPF progression.
September is Pulmonary Fibrosis Awareness Month, shedding light on the chronic and fatal lung disease known as Idiopathic Pulmonary Fibrosis (IPF). GRI Bio, a clinical-stage biopharmaceutical company, is dedicated to developing therapies that interrupt disease progression and restore the immune system's balance. Their lead drug, GRI-0621, inhibits the activity of iNKT cells involved in the inflammatory cascade leading to fibrotic disorders like IPF. Preclinical studies have shown promising results, and the drug has significant IP protection until 2038 or beyond. GRI Bio has collaborated with the Respiratory Translational Research Collaboration to further de-risk the drug's development program. The company is approaching IND filings and clearance for a phase 2a biomarker study.
GRI Bio, a clinical-stage biopharmaceutical company, is developing innovative therapies targeting NKT cells to treat inflammatory diseases such as Idiopathic Pulmonary Fibrosis (IPF) and Lupus. IPF is a chronic lung disease with limited treatment options and a significant unmet need. GRI Bio's lead program, GRI-0621, aims to inhibit iNKT cell activity and provide a more effective treatment option for IPF. The company is also developing type 2 NKT agonists for Lupus. With its unique approach and a library of proprietary compounds, GRI Bio has the potential to make a significant impact in the field of biopharmaceuticals and improve the lives of patients worldwide.
Biotech company FibroGen's stock crashed to a record low after its lead asset, pamrevlumab, failed to meet the preset bar for treating idiopathic pulmonary fibrosis. This is the second failure for the drug, which also failed to make a difference in Duchenne muscular dystrophy earlier this month. FibroGen will scrap two final-phase studies of pamrevlumab in idiopathic pulmonary fibrosis and work to extend its cash runway in 2026 through a cost-cutting plan. The fall of FibroGen stock marked a record low in massive volume.
FibroGen's pamrevlumab failed in a Phase III study for idiopathic pulmonary fibrosis, marking the company's third late-stage miss in two months. The drug was not better than placebo at a lung function test and did not delay disease progression. However, it was generally safe and well-tolerated.
FibroGen's Phase 3 ZEPHYRUS-1 trial evaluating the safety and efficacy of pamrevlumab in patients with idiopathic pulmonary fibrosis (IPF) did not meet the primary endpoint of change from baseline in forced vital capacity (FVC) at week 48. The study compared treatment with pamrevlumab to placebo. Pamrevlumab was generally safe and well tolerated. FibroGen plans to implement a significant cost reduction effort in the U.S. with the intent to extend its cash runway into 2026.